Huapont Life Sciences Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	11,291	11,293	11,508	11,409	13,021	12,290
Other Revenue	219.53	219.53	156.83	186.02	211.45	141.06
Revenue	11,510	11,512	11,665	11,595	13,232	12,431
Revenue Growth (YoY)	-0.52%	-1.31%	0.60%	-12.38%	6.44%	14.29%
Cost of Revenue	7,381	7,347	7,827	7,208	7,971	7,759
Gross Profit	4,129	4,165	3,838	4,387	5,261	4,672
Selling, General & Admin	2,262	2,310	2,259	2,550	2,904	2,753
Research & Development	310.78	341.62	375.32	419.14	385.24	329.47
Other Operating Expenses	121.74	113.68	114.96	103.47	89.41	80.78
Operating Expenses	2,781	2,848	2,770	3,080	3,386	3,188
Operating Income	1,348	1,317	1,068	1,307	1,875	1,484
Interest Expense	-291.7	-309.32	-349.97	-343.7	-434.01	-461.68
Interest & Investment Income	111.47	110.69	69.66	92.75	529.44	380.87
Currency Exchange Gain (Loss)	-2.04	-2.04	29.81	46.5	153.25	-31.74
Other Non Operating Income (Expenses)	-43.03	-11.94	-32.98	-43.03	-42.16	-55.59
EBT Excluding Unusual Items	1,123	1,105	784.79	1,059	2,082	1,316
Impairment of Goodwill	-56.62	-56.62	-707.56	-208.16	-491.85	-29.36
Gain (Loss) on Sale of Investments	1.54	3.97	-194.06	1.2	-4.84	8.52
Gain (Loss) on Sale of Assets	9.62	10.05	3.75	28.11	-21.26	-22.43
Asset Writedown	-80.43	-76.38	-108.59	-88.96	-31.51	-93.3
Other Unusual Items	72.14	72.14	61.16	101.04	90.16	101.87
Pretax Income	1,069	1,058	-160.51	892.39	1,623	1,281
Income Tax Expense	187.81	176.64	182.09	215.46	495.49	361.04
Earnings From Continuing Operations	881.35	881.23	-342.59	676.93	1,127	920.2
Minority Interest in Earnings	-197.67	-168.04	43.6	-374.81	-693.72	-252.4
Net Income	683.68	713.19	-298.99	302.12	433.48	667.81
Net Income to Common	683.68	713.19	-298.99	302.12	433.48	667.81
Net Income Growth	-	-	-	-30.30%	-35.09%	2.47%
Shares Outstanding (Basic)	1,973	1,973	1,975	1,980	1,980	1,980
Shares Outstanding (Diluted)	1,973	1,973	1,975	1,980	1,980	1,980
Shares Change (YoY)	-0.05%	-0.10%	-0.25%	-0.02%	0.02%	0.25%
EPS (Basic)	0.35	0.36	-0.15	0.15	0.22	0.34
EPS (Diluted)	0.35	0.36	-0.15	0.15	0.22	0.34
EPS Growth	-	-	-	-30.29%	-35.10%	2.21%
Free Cash Flow	1,698	1,458	669.02	305.35	1,277	13.19
Free Cash Flow Per Share	0.86	0.74	0.34	0.15	0.65	0.01
Dividend Per Share	0.450	0.450	-	0.220	0.220	0.220
Gross Margin	35.87%	36.18%	32.90%	37.83%	39.76%	37.58%
Operating Margin	11.71%	11.44%	9.16%	11.27%	14.17%	11.94%
Profit Margin	5.94%	6.19%	-2.56%	2.61%	3.28%	5.37%
Free Cash Flow Margin	14.75%	12.66%	5.73%	2.63%	9.65%	0.11%
EBITDA	2,386	2,335	2,003	2,165	2,647	2,200
EBITDA Margin	20.73%	20.28%	17.17%	18.67%	20.00%	17.70%
D&A For EBITDA	1,038	1,017	934.88	858.19	771.15	716.37
EBIT	1,348	1,317	1,068	1,307	1,875	1,484
EBIT Margin	11.71%	11.44%	9.16%	11.27%	14.17%	11.94%
Effective Tax Rate	17.57%	16.70%	-	24.14%	30.54%	28.18%
Revenue as Reported	11,510	11,512	11,665	11,595	13,232	12,431
Advertising Expenses	-	558.53	410.08	610.81	758.7	887.58

Source: S&P Global Market Intelligence. Standard template. Financial Sources.